Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 104Neoplasms 13Neoplasm Metastasis 8Sarcoma 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Leukemia, Myeloid, Acute 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Lung Neoplasms 4Liposarcoma 4Multiple Myeloma 3Head and Neck Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Breast Diseases 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Inflammation 2Estrogen Receptor-positive Breast Cancer 2Esophageal Squamous Cell Carcinoma 2

Interventions

Etoposide 19Carboplatin 19Ifosfamide 16Filgrastim 16Peripheral Blood Stem Cell Transplantation 13Paclitaxel 13Cisplatin 12Cyclophosphamide 10Thiotepa 7Therapeutics 5Radiotherapy 5Melphalan 5Busulfan 5Magnetic Resonance Spectroscopy 4Gemcitabine 4Flow Cytometry 4pegfilgrastim 3etoposide phosphate 3Surveys and Questionnaires 3Psychiatric Rehabilitation 3Methylprednisolone 3Methods 3Immunologic Techniques 3Granulocyte Colony-Stimulating Factor 3Epirubicin 3Dexamethasone 3Blood Specimen Collection 3Bleomycin 3tremelimumab 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Testicular Neoplasms × palbociclib × Clear all
NCT01037790 2021-03-11

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
304 enrolled 12 charts
BreastDermatologicGastrointestinalGenitourinary

Breast Neoplasms, Colonic Neoplasms, Melanoma, Rectal Neoplasms, Teratoma, Testicular Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡